- Home
- GHRS
GHRS
GH Research PLC
as 11-21-2024 11:34am EST
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.
| Founded: | 2018 | Country: | Ireland |
| Employees: | N/A | City: | N/A |
| Market Cap: | 470.3M | IPO Year: | 2021 |
| Target Price: | $35.67 | AVG Volume (30 days): | 66.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.79 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.05 - $14.99 | Next Earning Date: | 11-14-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest GH Research PLC News
GHRS Breaking Stock News: Dive into GHRS Ticker-Specific Updates for Smart Investing
Zacks
a day ago
Does GH Research (GHRS) Have the Potential to Rally 225.18% as Wall Street Analysts Expect?
Market Exclusive
3 days ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
GlobeNewswire
7 days ago
GH Research Reports Third Quarter 2024 Financial Results and Provides Business Updates
Simply Wall St.
11 days ago
We Think GH Research (NASDAQ:GHRS) Can Afford To Drive Business Growth
Zacks
2 months ago
GH Research (GHRS) Moves to Buy: Rationale Behind the Upgrade
Zacks
2 months ago
After Plunging -18.19% in 4 Weeks, Here's Why the Trend Might Reverse for GH Research (GHRS)
Market Exclusive
2 months ago
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
MT Newswires
3 months ago
GH Research Names Velichka Valcheva as CEO
Compare GHRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GHRS GH Research PLC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.